A PYMNTS Company

US: J&J can’t arbitrate Remicade antitrust case argues Rochester

By  |  March 10, 2019

A drug wholesaler is urging a federal appeals court to not send a lawsuit accusing Johnson & Johnson (J&J) of seeking to suppress competition for its blockbuster rheumatoid arthritis drug Remicade to arbitration.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Remicade has been on the market since receiving FDA approval in 1998. From 1998 to 2016, J&J had what the suit calls a monopoly on the market, as it was the only product that contained the active ingredient infliximab.

    Rochester Drug Cooperative told the 3rd US Circuit Court of Appeals in a brief on Thursday, March 7, that a federal judge in Philadelphia correctly determined its antitrust claims did not fall within the scope of an arbitration agreement it had signed with J&J.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.